$ASMB
Assembly Biosciences Inc

2023 Q4 Form 10-Q Financial Statement

#000095017023061134 Filed on November 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $7.163M $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.708M $4.220M
YoY Change 47.67% -19.94%
% of Gross Profit
Research & Development $11.01M $10.82M
YoY Change -31.14% -40.3%
% of Gross Profit
Depreciation & Amortization $80.00K $120.0K
YoY Change -35.48% -10.45%
% of Gross Profit
Operating Expenses $19.71M $15.05M
YoY Change -9.9% -35.7%
Operating Profit -$15.05M
YoY Change -35.7%
Interest Expense $1.622M $630.0K
YoY Change 178.22% 146.09%
% of Operating Profit
Other Income/Expense, Net $628.0K
YoY Change 145.31%
Pretax Income -$10.93M -$14.42M
YoY Change -51.2% -37.7%
Income Tax $33.00K
% Of Pretax Income
Net Earnings -$10.96M -$14.42M
YoY Change -51.05% -37.7%
Net Earnings / Revenue -153.04%
Basic Earnings Per Share -$0.27
Diluted Earnings Per Share -$2.40 -$0.27
COMMON SHARES
Basic Shares Outstanding 65.71M 52.61M
Diluted Shares Outstanding 52.57M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $130.2M $46.21M
YoY Change 42.18% -57.47%
Cash & Equivalents $19.84M $26.66M
Short-Term Investments $110.4M $19.55M
Other Short-Term Assets $3.497M $3.500M
YoY Change -20.76% -32.45%
Inventory
Prepaid Expenses
Receivables $43.00K $0.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $133.8M $49.67M
YoY Change 37.97% -56.84%
LONG-TERM ASSETS
Property, Plant & Equipment $385.0K $561.0K
YoY Change -48.18% -35.29%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $312.0K $552.0K
YoY Change -64.9% -65.78%
Total Long-Term Assets $3.036M $1.957M
YoY Change -37.1% -69.6%
TOTAL ASSETS
Total Short-Term Assets $133.8M $49.67M
Total Long-Term Assets $3.036M $1.957M
Total Assets $136.8M $51.63M
YoY Change 34.41% -57.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $461.0K $758.0K
YoY Change -81.51% -60.97%
Accrued Expenses $5.744M $3.886M
YoY Change -21.5% -31.66%
Deferred Revenue $30.92M
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $39.23M $7.132M
YoY Change 140.7% -53.87%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $56.50M $2.800M
YoY Change 1893.68% -23.31%
Total Long-Term Liabilities $56.50M $2.800M
YoY Change 1893.68% -23.31%
TOTAL LIABILITIES
Total Short-Term Liabilities $39.23M $7.132M
Total Long-Term Liabilities $56.50M $2.800M
Total Liabilities $95.73M $9.915M
YoY Change 400.4% -48.12%
SHAREHOLDERS EQUITY
Retained Earnings -$785.7M -$774.8M
YoY Change 8.45% 10.35%
Common Stock $826.9M $816.8M
YoY Change 2.34% 1.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $41.10M $41.71M
YoY Change
Total Liabilities & Shareholders Equity $136.8M $51.63M
YoY Change 34.41% -57.51%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$10.96M -$14.42M
YoY Change -51.05% -37.7%
Depreciation, Depletion And Amortization $80.00K $120.0K
YoY Change -35.48% -10.45%
Cash From Operating Activities $73.64M -$13.84M
YoY Change -482.48% -30.18%
INVESTING ACTIVITIES
Capital Expenditures $75.00K $130.0K
YoY Change -227.45%
Acquisitions
YoY Change
Other Investing Activities -$89.58M $19.02M
YoY Change -640.89% -39.68%
Cash From Investing Activities -$89.66M $18.88M
YoY Change -641.35% -39.93%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.188M 0.000
YoY Change 2002.52%
NET CHANGE
Cash From Operating Activities 73.64M -13.84M
Cash From Investing Activities -89.66M 18.88M
Cash From Financing Activities 9.188M 0.000
Net Change In Cash -6.827M 5.040M
YoY Change 202.75% -56.59%
FREE CASH FLOW
Cash From Operating Activities $73.64M -$13.84M
Capital Expenditures $75.00K $130.0K
Free Cash Flow $73.57M -$13.97M
YoY Change -482.09% -29.16%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001426800
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35005
dei Entity Registrant Name
EntityRegistrantName
ASSEMBLY BIOSCIENCES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-8729264
dei Entity Address Address Line1
EntityAddressAddressLine1
331 Oyster Point Blvd.
dei Entity Address Address Line2
EntityAddressAddressLine2
Fourth Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei City Area Code
CityAreaCode
833
dei Local Phone Number
LocalPhoneNumber
509-4583
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001
dei Trading Symbol
TradingSymbol
ASMB
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
65709112
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26656000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
52418000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
19554000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
39192000
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
944000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3462000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4413000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
49672000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
96967000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
561000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
743000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
844000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3195000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
552000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
889000
CY2023Q3 us-gaap Assets
Assets
51629000
CY2022Q4 us-gaap Assets
Assets
101794000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
758000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2493000
CY2023Q3 asmb Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
1619000
CY2022Q4 asmb Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
3122000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3886000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
7317000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
869000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3364000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
7132000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16296000
CY2023Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
2733000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
2733000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
50000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
101000
CY2023Q3 us-gaap Liabilities
Liabilities
9915000
CY2022Q4 us-gaap Liabilities
Liabilities
19130000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52614194
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52614194
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48894973
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48894973
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
53000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
49000
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
816722000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
807938000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-275000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-803000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-774786000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-724520000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
41714000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
82664000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
51629000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
101794000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10824000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18130000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
37894000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
53127000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4224000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5271000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14201000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18009000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
15048000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
23401000
us-gaap Operating Expenses
OperatingExpenses
52095000
us-gaap Operating Expenses
OperatingExpenses
71136000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-15048000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-23401000
us-gaap Operating Income Loss
OperatingIncomeLoss
-52095000
us-gaap Operating Income Loss
OperatingIncomeLoss
-71136000
CY2023Q3 us-gaap Interest Income Other
InterestIncomeOther
628000
CY2022Q3 us-gaap Interest Income Other
InterestIncomeOther
256000
us-gaap Interest Income Other
InterestIncomeOther
1829000
us-gaap Interest Income Other
InterestIncomeOther
439000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
628000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
256000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1829000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
439000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-14420000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-23145000
us-gaap Net Income Loss
NetIncomeLoss
-50266000
us-gaap Net Income Loss
NetIncomeLoss
-70697000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
50000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
528000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-580000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14370000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23146000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-49738000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-71277000
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.97
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.97
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.46
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.46
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52565333
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52565333
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48448399
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48448399
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51951123
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51951123
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48289501
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48289501
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
54949000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
50000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1135000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-14420000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
41714000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
123980000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1570000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-23145000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
102404000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
82664000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4546000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
80000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
528000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4162000
us-gaap Net Income Loss
NetIncomeLoss
-50266000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
41714000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
168929000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
177000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-580000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4575000
us-gaap Net Income Loss
NetIncomeLoss
-70697000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
102404000
us-gaap Profit Loss
ProfitLoss
-50266000
us-gaap Profit Loss
ProfitLoss
-70697000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
366000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
374000
us-gaap Share Based Compensation
ShareBasedCompensation
4160000
us-gaap Share Based Compensation
ShareBasedCompensation
4580000
asmb Accretion Amortization Of Investments In Marketable Debt Securities
AccretionAmortizationOfInvestmentsInMarketableDebtSecurities
534000
asmb Accretion Amortization Of Investments In Marketable Debt Securities
AccretionAmortizationOfInvestmentsInMarketableDebtSecurities
-234000
asmb Noncash Rent Expense
NoncashRentExpense
2525000
asmb Noncash Rent Expense
NoncashRentExpense
2644000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-944000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
910000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-951000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2060000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-337000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-90000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1735000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-717000
asmb Increase Decrease In Accrued Research And Development Expenses
IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
-1503000
asmb Increase Decrease In Accrued Research And Development Expenses
IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
1062000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-3429000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-1182000
asmb Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-2720000
asmb Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-2747000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-50904000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-65209000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
46315000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
66000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
184000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
102000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
25615000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
18820000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
27000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
20516000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
74078000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4546000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
asmb Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
80000
asmb Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
177000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4626000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
177000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-25762000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
9046000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
52418000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
45627000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
26656000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
54673000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
171000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
asmb Number Of Approved Products
NumberOfApprovedProducts
0
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span></p><p style="text-indent:0;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant estimates inherent in the preparation of the accompanying unaudited condensed consolidated financial statements include estimates of costs incurred but not yet invoiced for research and development accruals.</span></p><p style="text-indent:0;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible these external factors could have an effect on the Company’s estimates and could cause actual results to differ materially from those estimates and assumptions.</span></p>
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-14420000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-23145000
us-gaap Net Income Loss
NetIncomeLoss
-50266000
us-gaap Net Income Loss
NetIncomeLoss
-70697000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52565333
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52565333
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48448399
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48448399
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51951123
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51951123
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48289501
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48289501
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.97
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.97
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.46
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.46
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11114903
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11381036
CY2023Q3 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
19556000
CY2023Q3 asmb Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
1000
CY2023Q3 asmb Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent
3000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
19554000
CY2023Q3 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Amortized Cost
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesAmortizedCost
45310000
CY2023Q3 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Gross Unrealized Gain
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesGrossUnrealizedGain
1000
CY2023Q3 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Gross Unrealized Loss
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesGrossUnrealizedLoss
3000
CY2023Q3 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Estimated Fair Value
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesEstimatedFairValue
45308000
CY2022Q4 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
39722000
CY2022Q4 asmb Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
0
CY2022Q4 asmb Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent
530000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
39192000
CY2022Q4 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Amortized Cost
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesAmortizedCost
89398000
CY2022Q4 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Gross Unrealized Gain
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesGrossUnrealizedGain
0
CY2022Q4 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Gross Unrealized Loss
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesGrossUnrealizedLoss
530000
CY2022Q4 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Estimated Fair Value
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesEstimatedFairValue
88868000
CY2023Q3 asmb Accured Interest Receivable
AccuredInterestReceivable
100000
CY2022Q4 asmb Accured Interest Receivable
AccuredInterestReceivable
300000
CY2023Q3 asmb Fair Value Assets Between Levels Transfers Amount
FairValueAssetsBetweenLevelsTransfersAmount
0
CY2022Q4 asmb Fair Value Assets Between Levels Transfers Amount
FairValueAssetsBetweenLevelsTransfersAmount
0
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3738000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6228000
CY2023Q3 asmb Accrued Restructuring Charges Current
AccruedRestructuringChargesCurrent
0
CY2022Q4 asmb Accrued Restructuring Charges Current
AccruedRestructuringChargesCurrent
599000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
148000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
490000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3886000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7317000
CY2022Q3 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.30
CY2023Q3 asmb Cumulative Restructuring Charges
CumulativeRestructuringCharges
1100000
CY2022Q3 us-gaap Severance Costs1
SeveranceCosts1
1000000
CY2022Q3 asmb Restructuring One Time Termination Cost
RestructuringOneTimeTerminationCost
800000
CY2022Q3 asmb Restructuring Costs Reversal Of Stock Based Compensation Expense
RestructuringCostsReversalOfStockBasedCompensationExpense
700000
CY2023Q3 us-gaap Restructuring Charges
RestructuringCharges
0
us-gaap Restructuring Charges
RestructuringCharges
0
CY2022Q3 us-gaap Restructuring Charges
RestructuringCharges
800000
us-gaap Restructuring Charges
RestructuringCharges
1800000
asmb Schedule Of Accrued Restructuring Charges Table Textblock
ScheduleOfAccruedRestructuringChargesTableTextblock
<p style="text-indent:0;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A summary of accrued restructuring charges, included as a component of other accrued expenses on the Company's condensed consolidated balance sheet as of </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023, is as follows (in thousands):</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.783%;"></td> <td style="width:2.771%;"></td> <td style="width:1%;"></td> <td style="width:27.446%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cef1fe;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued balance as of December 31, 2022</span></p></td> <td style="background-color:#cef1fe;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cef1fe;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cef1fe;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">599</span></p></td> <td style="background-color:#cef1fe;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Reductions for cash payments</span></p></td> <td style="background-color:#ffffff;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">599</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cef1fe;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued balance as of September 30, 2023</span></p></td> <td style="background-color:#cef1fe;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="border-top:0.5pt solid #000000;background-color:#cef1fe;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="border-top:0.5pt solid #000000;background-color:#cef1fe;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="border-top:0.5pt solid #000000;background-color:#cef1fe;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> </table>
CY2022Q4 asmb Accrued Restructuring Charges Current
AccruedRestructuringChargesCurrent
599000
us-gaap Payments For Restructuring
PaymentsForRestructuring
599000
CY2023Q3 asmb Accrued Restructuring Charges Current
AccruedRestructuringChargesCurrent
0
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1135000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1556000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4160000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4580000
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
3700000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y6M
CY2023Q3 asmb Share Based Compensation Arrangement Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementFairValueAssumptionsExercisePrice
0.98
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q3 us-gaap Purchase Commitment Remaining Minimum Amount Committed
PurchaseCommitmentRemainingMinimumAmountCommitted
800000
asmb Milestone Payment Diligence Maintenance Fees
MilestonePaymentDiligenceMaintenanceFees
100000
asmb Milestone Payment Diligence Maintenance Fees
MilestonePaymentDiligenceMaintenanceFees
100000
CY2023Q3 us-gaap Lessee Operating Lease Lease Not Yet Commenced Term Of Contract1
LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1
P24M
CY2023Q3 asmb Monthly Sublease Base Rent
MonthlySubleaseBaseRent
100000
CY2023Q3 asmb Lessee Operating Lease Lease Not Yet Commenced Payments Due
LesseeOperatingLeaseLeaseNotYetCommencedPaymentsDue
2600000
CY2023Q3 us-gaap Lessee Operating Lease Lease Not Yet Commenced Option To Extend
LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend
The Company has the option to extend the sublease through September 30, 2029.
CY2023Q3 us-gaap Lessee Operating Lease Lease Not Yet Commenced Existence Of Option To Extend
LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend
true
CY2023Q3 asmb Lessee Operating Lease Lease Not Yet Commenced Right Of Use Asset
LesseeOperatingLeaseLeaseNotYetCommencedRightOfUseAsset
0
CY2023Q3 asmb Lessee Operating Lease Lease Not Yet Commenced Lease Liability
LesseeOperatingLeaseLeaseNotYetCommencedLeaseLiability
0

Files In Submission

Name View Source Status
0000950170-23-061134-index-headers.html Edgar Link pending
0000950170-23-061134-index.html Edgar Link pending
0000950170-23-061134.txt Edgar Link pending
0000950170-23-061134-xbrl.zip Edgar Link pending
asmb-20230930.htm Edgar Link pending
asmb-20230930.xsd Edgar Link pending
asmb-ex10_1.htm Edgar Link pending
asmb-ex31_1.htm Edgar Link pending
asmb-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
asmb-20230930_cal.xml Edgar Link unprocessable
asmb-20230930_def.xml Edgar Link unprocessable
asmb-20230930_lab.xml Edgar Link unprocessable
asmb-20230930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
asmb-20230930_htm.xml Edgar Link completed
img33231229_0.jpg Edgar Link pending
img33231229_1.jpg Edgar Link pending
img33231229_10.jpg Edgar Link pending
img33231229_11.jpg Edgar Link pending
img33231229_12.jpg Edgar Link pending
img33231229_2.jpg Edgar Link pending
img33231229_3.jpg Edgar Link pending
img33231229_4.jpg Edgar Link pending
img33231229_5.jpg Edgar Link pending
img33231229_6.jpg Edgar Link pending
img33231229_7.jpg Edgar Link pending
img33231229_8.jpg Edgar Link pending
img33231229_9.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending